At #JPM23, another rare disease buyout as Ipsen acquires Albireo for $952M
Before most JPMers arose Monday morning, Ipsen announced that it is buying rare disease biotech Albireo Pharma.
That’s the second deal disclosed Monday morning, along with AstraZeneca grabbing cardiovascular upstart CinCor Pharma. With the Chiesi-Amryt rare disease deal from Sunday night, that’s three M&A announcements to kick off the annual healthcare investment banking conference, albeit the trio of deals is relatively small in size, with none surpassing $2 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.